AMP Capital Investors Ltd lessened its stake in shares of Allergan plc (NYSE:AGN) by 5.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 89,128 shares of the company’s stock after selling 4,841 shares during the quarter. AMP Capital Investors Ltd’s holdings in Allergan were worth $14,579,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of AGN. Boston Partners lifted its stake in shares of Allergan by 22.3% during the 3rd quarter. Boston Partners now owns 35,835 shares of the company’s stock worth $7,344,000 after buying an additional 6,527 shares during the last quarter. Jarislowsky Fraser Ltd lifted its stake in shares of Allergan by 71.5% during the 3rd quarter. Jarislowsky Fraser Ltd now owns 2,147 shares of the company’s stock worth $440,000 after buying an additional 895 shares during the last quarter. Archon Partners LLC lifted its stake in shares of Allergan by 23.3% during the 3rd quarter. Archon Partners LLC now owns 37,041 shares of the company’s stock worth $7,592,000 after buying an additional 7,000 shares during the last quarter. Security Asset Management lifted its stake in shares of Allergan by 16.8% during the 3rd quarter. Security Asset Management now owns 9,513 shares of the company’s stock worth $1,950,000 after buying an additional 1,365 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in shares of Allergan by 2.2% during the 3rd quarter. New York State Common Retirement Fund now owns 1,135,114 shares of the company’s stock worth $232,642,000 after buying an additional 24,627 shares during the last quarter. Institutional investors own 78.40% of the company’s stock.
A number of research firms have recently issued reports on AGN. Leerink Swann raised their target price on shares of Allergan from $237.00 to $242.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Vetr cut shares of Allergan from a “buy” rating to a “hold” rating and set a $180.97 target price for the company. in a research note on Wednesday, January 10th. Argus cut shares of Allergan from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $256.80 to $160.07 in a research note on Thursday, December 7th. Cantor Fitzgerald reiterated a “hold” rating and issued a $191.00 price objective on shares of Allergan in a research note on Tuesday, February 6th. Finally, Morgan Stanley upgraded shares of Allergan from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $171.92 to $200.00 in a research note on Wednesday, November 29th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Allergan presently has an average rating of “Buy” and an average target price of $225.03.
Allergan (NYSE:AGN) last released its earnings results on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, beating the consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The firm had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. During the same period last year, the firm earned $3.90 EPS. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. equities research analysts predict that Allergan plc will post 15.58 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be issued a $0.72 dividend. This is a positive change from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a yield of 1.82%. The ex-dividend date is Tuesday, February 27th. Allergan’s dividend payout ratio (DPR) is currently -24.02%.
In other news, CFO Matthew M. Walsh bought 2,000 shares of the firm’s stock in a transaction on Wednesday, February 21st. The shares were purchased at an average cost of $160.94 per share, with a total value of $321,880.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Joseph H. Boccuzi bought 900 shares of the firm’s stock in a transaction on Monday, March 5th. The stock was purchased at an average cost of $143.42 per share, for a total transaction of $129,078.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 7,200 shares of company stock worth $1,108,267. Insiders own 0.36% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/03/13/amp-capital-investors-ltd-cuts-stake-in-allergan-plc-agn.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.